BIOLOGICAL ACTIVITY OF FLX475, AN ORAL CCR4 ANTAGONIST, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN ADVANCED CANCER

Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2023
This article has no abstract
Epistemonikos ID: 52796411569950a7bebc52304cd10ebc5f07d430
First added on: Feb 17, 2025